Uncommon Denominator
VC Fund
New York, United States
Uncommon Denominator is a venture capital firm that focuses on consumer, SaaS, and frontier tech. The firm also invests in consumer brands that hit a psychological nerve, software companies that help other businesses make more money or spend less of it, and occasionally in frontier technologies.It was founded in 2018 and headquartered in NewYork, United States.
- Total investments:
- 39
- Last investment:
- Lead investor:
- 5%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Uncommon Denominator invests in
Stages Uncommon Denominator invests in
Countries Uncommon Denominator invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
David Honig
|
|||
Doug Perlson
|
|||
Skiddy von Stade
|
|||
2 more contacts available
Investment Focus
Industry
- Biotechnology 7 (18%)
- Software 6 (15%)
- E-Commerce 5 (13%)
- Food and Beverage 4 (10%)
- B2B 3 (8%)
Stage
- Seed 19 (49%)
- Funding Round 7 (18%)
- Series A 5 (13%)
- Pre-Seed 1 (3%)
- Series B 1 (3%)
Country
- United States 27 (69%)
- Canada 1 (3%)
- United Kingdom 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
David Honig
Managing Partner&Founder
|
Managing Partner&Founder | Total investments: 1 | Find email | |
|
Doug Perlson
Partner
|
Partner | Total investments: 0 | Find email | |
|
Skiddy von Stade
Partner
|
Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Rogue protein snacks
|
Rogue protein snacks is a high-protein snack company offering chips and puffs with 20g protein per serving, active probiotics for gut health, no seed oils, and no artificial ingredients. | $2.5M / Pre-Seed / May 11, 2026 | |
Kanvas Biosciences
|
Kanvas Biosciences developed cutting-edge imaging technology for microbial detection, providing unmatched speed, breadth, and adaptability. Kanvas aims to transform microbial research and infectious disease diagnostics through innovative imaging technology of the next generation. | $48M / Series A / May 05, 2026 | |
Pickaxe
|
Pickaxe allows non-technical creative professionals to test prompts, deploy them as tools at scale, and continuously improve their tools through real-time monitoring. | $3.8M / Seed / Sep 16, 2025 | |
Final Boss Sour
|
Final Boss Sour is a gaming-themed snack brand offering a healthier alternative to traditional sour treats. Inspired by retro gaming aesthetics, our snacks deliver bold flavors and a fun experience for gamers of all ages. | $4M / Seed / May 20, 2025 | |
Terrain Bio
|
Terrain BioSciences is in the field of RNA-based therapeutics and vaccine development. Leveraging advanced AI and proprietary manufacturing platforms, Terrain BioSciences addresses the challenges of designing, selecting, manufacturing, and delivering optimal RNA sequences. Terrain BioSciences collaborates with over a dozen biotech firms to enhancethe expression, durability, and manufacturability of RNA sequences, significantly accelerating their path to clinical application. With a focus on personalized cancer vaccines and other RNA-based modalities, Terrain BioSciences is at the forefront of the next generation of programmable medicines. | $9M / Seed / Feb 12, 2025 | |
|
Final Boss Sour
|
Final Boss Sour is a gaming-themed snack brand offering a healthier alternative to traditional sour treats. Inspired by retro gaming aesthetics, our snacks deliver bold flavors and a fun experience for gamers of all ages. | $3M / Seed / Oct 29, 2024 | |
North.cloud
|
North helps companies automate their AWS savings. By connecting to our analytics engine companies can quickly spot their cost savings opportunities based on their real life cloud usage trends. North then automates the best discounting possible for those products while making sure customers never pay for an unused discount commitment again. | $2.3M / Seed / Jun 20, 2024 | |
|
Kanvas Biosciences
|
Kanvas Biosciences developed cutting-edge imaging technology for microbial detection, providing unmatched speed, breadth, and adaptability. Kanvas aims to transform microbial research and infectious disease diagnostics through innovative imaging technology of the next generation. | $12M / Seed / Jun 22, 2023 | |
Dandi Technologies
|
Dandi is the analytics platform for advancing equity, inclusion, and diversity. | $3.7M / Seed / Aug 22, 2022 | |
Mytide Therapeutics
|
Mytide is committed to providing peptides to serve a diverse array of applications. They intend to work closely with partners to overcome challenges in synthesizing and purifying particular classes of peptides of interest, identify useful peptide modifications, and design and construct peptide libraries. They provide initial partners access totheir cloud platform for immediate ordering, properties calculator, order tracking, and interactive data display. | $7M / Series A / Mar 08, 2022 | |
| See all 39 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Uncommon Denominator invest in?
Uncommon Denominator invests primarily in Biotechnology, Software and E-Commerce startups, most often at Seed and Funding Round stage. Most of the 39 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Uncommon Denominator?
Public channels for Uncommon Denominator include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Uncommon Denominator?
The team at Uncommon Denominator includes David Honig (Managing Partner&Founder), Doug Perlson (Partner) and Skiddy von Stade (Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
